138 related articles for article (PubMed ID: 34155198)
1. Detection of minimal residual disease by next generation sequencing in AL amyloidosis.
Sarosiek S; Varga C; Jacob A; Fulciniti MT; Munshi N; Sanchorawala V
Blood Cancer J; 2021 Jun; 11(6):117. PubMed ID: 34155198
[No Abstract] [Full Text] [Related]
2. Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.
Kastritis E; Kostopoulos IV; Terpos E; Paiva B; Fotiou D; Gavriatopoulou M; Kanellias N; Ziogas DC; Roussou M; Migkou M; Eleutherakis-Papaiakovou E; Trougakos IP; Tsitsilonis O; Dimopoulos MA
Blood Cancer J; 2018 May; 8(5):46. PubMed ID: 29795385
[No Abstract] [Full Text] [Related]
3. Minimal residual disease (MRD) assessment by flow cytometry after ASCT for AL amyloidosis: are we there yet?
Lee H; Duggan P; Neri P; Tay J; Bahlis NJ; Jimenez-Zepeda VH
Bone Marrow Transplant; 2017 Jun; 52(6):915-917. PubMed ID: 28287637
[No Abstract] [Full Text] [Related]
4. Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis.
Muchtar E; Dispenzieri A; Jevremovic D; Dingli D; Buadi FK; Lacy MQ; Gonsalves W; Warsame R; Kourelis TV; Hayman SR; Kapoor P; Leung N; Russell S; Lust JA; Lin Y; Go RS; Zeldenrust S; Kyle RA; Rajkumar SV; Kumar SK; Gertz MA
Amyloid; 2020 Mar; 27(1):13-16. PubMed ID: 31544536
[TBL] [Abstract][Full Text] [Related]
5. Next generation flow cytometry for MRD detection in patients with AL amyloidosis.
Kastritis E; Kostopoulos IV; Theodorakakou F; Fotiou D; Gavriatopoulou M; Migkou M; Tselegkidi MI; Roussou M; Papathoma A; Eleutherakis-Papaioakovou E; Dialoupi I; Kanellias N; Ntalianis A; Rousakis P; Trougakos IP; Tsitsilonis O; Gakiopoulou C; Terpos E; Dimopoulos MA
Amyloid; 2021 Mar; 28(1):19-23. PubMed ID: 32783569
[TBL] [Abstract][Full Text] [Related]
6. Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response.
Palladini G; Milani P; Basset M; Russo F; Lavatelli F; Nuvolone M; Ferraro G; Bozzola M; Foli A; Perlini S; Merlini G
Amyloid; 2017 Mar; 24(sup1):54-55. PubMed ID: 28434293
[No Abstract] [Full Text] [Related]
7. Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival.
Muchtar E; Dispenzieri A; Kumar SK; Buadi FK; Lacy MQ; Zeldenrust S; Hayman SR; Leung N; Kourelis TV; Gonsalves W; Chakraborty R; Russell S; Dingli D; Lust JA; Lin Y; Kapoor P; Go R; Kyle RA; Rajkumar SV; Gertz MA
Amyloid; 2017 Mar; 24(sup1):40-41. PubMed ID: 28434371
[No Abstract] [Full Text] [Related]
8. Involved free light chains <10 mg/L with treatment predict better outcomes in systemic light-chain amyloidosis.
Godara A; Toskic D; Albanese J; Rosenthal B; Siddiqui NS; Kugelmass A; Zhou P; Fogaren T; Varga C; Landau HJ; Comenzo RL
Am J Hematol; 2021 Jan; 96(1):E20-E23. PubMed ID: 33068021
[No Abstract] [Full Text] [Related]
9. Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis.
Landau H; Lahoud O; Devlin S; Lendvai N; Chung DJ; Dogan A; Landgren CO; Giralt S; Hassoun H
Biol Blood Marrow Transplant; 2020 Jan; 26(1):204-208. PubMed ID: 31446197
[TBL] [Abstract][Full Text] [Related]
10. Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis.
Dispenzieri A; Arendt B; Dasari S; Kohlhagen M; Kourelis T; Kumar SK; Leung N; Muchtar E; Buadi FK; Warsame R; Kyle RA; Lacy MQ; Dingli D; Kapoor P; Gonsalves WI; Go RS; Hayman SR; Hwa YL; Fonder A; Hobbs M; Jevremovic D; Lust JA; Zeldenrust S; Russell SJ; Rajkumar SV; Gertz MA; Murray D
Blood Cancer J; 2020 Feb; 10(2):20. PubMed ID: 32098948
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers in Immunoglobulin Light Chain Amyloidosis.
Kufová Z; Sevcikova T; Growkova K; Vojta P; Filipová J; Adam Z; Pour L; Penka M; Rysava R; Němec P; Brozova L; Vychytilova P; Jurczyszyn A; Grosicki S; Barchnicka A; Hajdúch M; Simicek M; Hájek R
Klin Onkol; 2017; 30(Supplementum2):60-67. PubMed ID: 28903572
[TBL] [Abstract][Full Text] [Related]
12. Diverse patterns of antibody variable gene repertoire disruption in patients with amyloid light chain (AL) amyloidosis.
Chen EC; Rubinstein S; Soto C; Bombardi RG; Day SB; Myers L; Zaytsev A; Majedi M; Cornell RF; Crowe JE
PLoS One; 2020; 15(7):e0235713. PubMed ID: 32634163
[TBL] [Abstract][Full Text] [Related]
13. Identification of clonal immunoglobulin λ light-chain gene rearrangements in AL amyloidosis using next-generation sequencing.
Kimura K; Tsukamoto S; Miyazaki K; Kawajiri-Manako C; Ishii A; Rahmutulla B; Fukuyo M; Oshima-Hasegawa N; Mitsukawa S; Takeda Y; Mimura N; Takeuchi M; Ohwada C; Iseki T; Matsusaka K; Sanada M; Yokote K; Kaneda A; Ishida T; Suzuki K; Nakaseko C; Sakaida E
Exp Hematol; 2021 Sep; 101-102():34-41.e4. PubMed ID: 34411686
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis.
Palladini G; Paiva B; Wechalekar A; Massa M; Milani P; Lasa M; Ravichandran S; Krsnik I; Basset M; Burgos L; Nuvolone M; Lecumberri R; Foli A; Puig N; Sesta MA; Bozzola M; Cascino P; Nevone A; Ripepi J; Berti P; Casarini S; Annibali O; Orfao A; San-Miguel J; Merlini G
Blood Cancer J; 2021 Feb; 11(2):34. PubMed ID: 33594045
[TBL] [Abstract][Full Text] [Related]
15. Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the Treatment of Newly Diagnosed AL Amyloidosis: Impact of Response on Survival Outcomes.
Diaz-Pallares C; Lee H; Luider J; Duggan P; Neri P; Tay J; MacCulloch S; Bahlis NJ; Jimenez-Zepeda VH
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):394-399. PubMed ID: 32146104
[TBL] [Abstract][Full Text] [Related]
16. Establishment of brain natriuretic peptide - based criteria for evaluating cardiac response to treatment in light chain (AL) amyloidosis.
Lilleness B; Doros G; Ruberg FL; Sanchorawala V
Br J Haematol; 2020 Feb; 188(3):424-427. PubMed ID: 31515797
[TBL] [Abstract][Full Text] [Related]
17. Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis.
Kastritis E; Papassotiriou I; Merlini G; Milani P; Terpos E; Basset M; Akalestos A; Russo F; Psimenou E; Apostolakou F; Roussou M; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Fotiou D; Ziogas DC; Papadopoulou E; Pamboucas C; Dimopoulos MA; Palladini G
Blood; 2018 Apr; 131(14):1568-1575. PubMed ID: 29386197
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.
Al Saleh AS; Sidiqi MH; Muchtar E; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Warsame RM; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1520-1525. PubMed ID: 31054986
[TBL] [Abstract][Full Text] [Related]
19. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features.
Sidana S; Larson DP; Greipp PT; He R; McPhail ED; Dispenzieri A; Murray DL; Dasari S; Ansell SM; Muchtar E; Gonsalves WI; Kourelis TV; Ramirez-Alvarado M; Kapoor P; Rajkumar SV; Lacy MQ; Buadi FK; Leung N; Kyle RA; Kumar SK; King RL; Gertz MA
Leukemia; 2020 May; 34(5):1373-1382. PubMed ID: 31780812
[TBL] [Abstract][Full Text] [Related]
20. AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival.
Ozga M; Zhao Q; Benson D; Elder P; Williams N; Bumma N; Rosko A; Chaudhry M; Khan A; Devarakonda S; Kahwash R; Vallakati A; Campbell C; Parikh SV; Almaani S; Prosek J; Bittengle J; Pfund K; LoRusso S; Freimer M; Redder E; Efebera Y; Sharma N
Cancer Med; 2021 Feb; 10(3):965-973. PubMed ID: 33347707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
